Professor Władysław Lasoń, PhD


Professor Władysław Lasoń, PhD
Position
Professor

Wladyslaw Lason  got his M.Sc. at  Faculty of Pharmacy of the Medical Academy in Kraków in 1980 and Ph.D in the Institute of Pharmacology Polish Academy of Sciences, Kraków in 1984. He received post-doctoral training at the Department of Anatomy and Cell Biology, School of Medicine, East Carolina University,  Greenville, NC, USA, and at the Department of Comparative and Physiological Psychology at the Nijmegen University in the Netherlands.  In the years  1993 - 2020 he has served as Head of the  Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology Polish Academy, and currently he is a Professor in this unit. His main research interests are  focused on basic mechanisms of epilepsy, depression and neurodegenerative diseases. He has co-authored more than 260 peer-reviewed publications.

The most recent publications:

1.      Jantas D, Chwastek J, Malarz J, Stojakowska A, Lasoń W. Neuroprotective Effects of Methyl Caffeate against Hydrogen Peroxide-Induced Cell Damage: Involvement of Caspase 3 and Cathepsin D Inhibition. Biomolecules. 2020 Nov 9;10(11):1530

2.      Panek M, Kawalec P, Pilc A, Lasoń W. Developments in the discovery and design of intranasal antidepressants. Expert Opin Drug Discov. 2020 Oct;15(10):1145-1164

3.      Jantas D, Chwastek J, Grygier B, Lasoń W. Neuroprotective Effects of Necrostatin-1 Against Oxidative Stress-Induced Cell Damage: an Involvement of Cathepsin D Inhibition. Neurotox Res. 2020 Mar;37(3):525-542

4.      Kajta M, Rzemieniec J, Wnuk A, Lasoń W. Triclocarban impairs autophagy in neuronal cells and disrupts estrogen receptor signaling via hypermethylation of specific genes. Sci Total Environ. 2020 Jan 20;701:134818

5.      Basta-Kaim A, Ślusarczyk J, Szczepanowicz K, Warszyński P, Leśkiewicz M, Regulska M, Trojan E, Lasoń W. Protective effects of polydatin in free and nanocapsulated form on changes caused by lipopolysaccharide in hippocampal organotypic cultures. Pharmacol Rep. 2019 Aug;71(4):603-613



  • GRIEG 1. Theranostic nanocarriers for drug delivery in central nervous system disorders. - 2021-12-13 - 2024-04-12
    Grant GRIEG 1, 2019/34/H/ST5/00578; 2021.12.13-2024.04.12
  • OPUS 20. New generation teranostatic nanocarriers for detection, diagnosis and neuroprotective treatment of ischemic stroke brain damage. - 2021-07-16 - 2025-07-15
    Grant NCN OPUS 20, 2020/39/B/NZ7/01913; 2021.07.16-2025.07.15
  • Grant NanoNeucar - 2013-10-01 - 2016-09-30
    Nanoparticulate delivery systems for therapies against neurodegenerative diseases : Estimation of nanoparticle delivery system in  efficacy of putative neuroprotectants in in vitro models. (Pol-Nor/199523/64/2013)